ACUMEN PHARMACEUTICALS INC (ABOS)
Health Care · biotechnology · NASDAQ
Acumen Pharmaceuticals is developing a precision immunotherapy targeting toxic amyloid-beta oligomers to provide a disease-modifying treatment for Alzheimer’s disease.
What ACUMEN PHARMACEUTICALS INC does
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for Alzheimer’s disease. Its lead candidate, sabirnetug (ACU193), is an IgG2 monoclonal antibody designed to selectively target toxic soluble amyloid-beta oligomers (AβOs). The company is also developing an Enhanced Brain Delivery (EBD) program that utilizes blood-brain barrier-penetrating technology to create next-generation, subcutaneous-administered antibody treatments.
Recent developments
In June 2026, the company nominated ACU301 and ACU401 as development candidates in its EBD program following the exercise of its option with JCR Pharmaceuticals. The company expects to announce top-line results for its Phase 2 ALTITUDE-AD clinical trial of sabirnetug in late 2026 and continues to target a mid-2027 IND submission for an EBD lead candidate.
From ACUMEN PHARMACEUTICALS INC's filing of 2026-08-12.
Themes: Alzheimer's disease, immunotherapy, neurodegenerative diseases, monoclonal antibodies, blood-brain barrier delivery
Fundamentals
- Price$2.10 as of 2026-10-08 close
- Market cap$152M as of 2026-08-07 (share count; price 2026-10-08)
- 1-year return+11.7% 2025-10-08 close $1.88 → 2026-10-08 close $2.10
- P/En/a negative earnings
- ROE-172.3% FY2025, SEC XBRL
- Debt / equity0.35 as of 2026-09-03
- Beta1.38 as of 2026-09-03
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How ABOS compares in its sector
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ACUMEN PHARMACEUTICALS INC looks technically
ACUMEN PHARMACEUTICALS INC (ABOS) is trading 16.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 268 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 41.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 16.2% below its 200-day average, the long-term trend line — a long-term downtrend | -16.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.60 | $2.60 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.51 | $2.51 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 30 calendar days ago — the swings before that are what the structure reading is measured on | 30 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 3.29. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 268 trading days ago — a "golden cross", a bullish long-term signal | 268 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend) | 24.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 35.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($2.00 to $2.71) — its "stochastic" reading is 14 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 14.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 22 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.60 | $3.60 |
|---|---|---|
| From the 52-week high | it is 41.7% below its 52-week high (its highest price of the past year) | -41.7% |
| Above the 52-week low | it is 40.0% above its 52-week low (its lowest price of the past year) | +40.0% |
| Below the 52-week high | it is 41.7% below its highest point of the past year | 41.7% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $11.31 (set on 2023-07-17) | $11.31 |
| Given back of the 52-week move | over the past year its closes ranged ($1.55 to $3.37), and it has given back well over two thirds of its rise from last year’s low — 70% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.19 to $2.25. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 69.8% |
| From the all-time high | it is 81.4% below its all-time high | -81.4% |
| Nearest price level | it is sitting right on a support level at $2.10 — a price it turned at four times since 2026-05-19, most recently on 2026-07-29. Since 2024-10-08 it has 6 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.2% |
| All-time low | its lowest closing price on record is $0.8551 (set on 2025-04-21) | $0.8551 |
| Above the all-time low | it is 145.6% above its all-time low | +145.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 87% of the past ~6 months) | 87th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1768 between its high and its low — about 8.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1768 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.81 and $2.96 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.81 – $2.38 – $2.96 |
| Typical daily range (% of price) | its price moves about 8.4% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.4% |
| Stretch from the 200-day average | it is trading 2.3 daily ranges below its 200-day average price (16.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.01× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Gap filled | a 3.1% gap up opened on 2026-09-17 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 34.6 percentage points (the stock lost 33.5% while the market gained 1.0%) | -34.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 26.9 percentage points (the stock lost 23.1% while the market gained 3.8%) | -26.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 41.4 percentage points (the stock lost 23.9% while the market gained 17.5%) | -41.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 3.3 percentage points (the stock gained 11.7% while the market gained 15.0%) | -3.3% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 23% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 8.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -22.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 18% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.56 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -17.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 19% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.58 — a volume-weighted average of daily closes over 41 sessions, not a true tick-by-tick VWAP. | -18.6% |
Price levels it has turned at before
ABOS last closed at $2.10 on 2026-10-08. Since 2024-10-08 it has turned at 6 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.10 | Support | 0.2% below the last close | turned there four times · 2026-05-19 to 2026-07-29 |
| $2.39 | Resistance | 13.9% above the last close | turned there three times · 2025-10-15 to 2026-07-28 |
| $2.46 | Resistance | 17.1% above the last close | turned there three times · 2024-11-25 to 2026-04-13 |
| $1.68 | Support | 20.0% below the last close | turned there twice · 2024-12-30 to 2026-01-12 |
| $1.51 | Support | 28.3% below the last close | turned there three times · 2025-02-18 to 2025-11-17 |
| $2.75 | Resistance | 30.8% above the last close | turned there twice · 2026-05-11 to 2026-08-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $3.29.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 18 trading days, since 2026-09-15.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Printed a doji candle · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$7.60 range $5.00 – $10.00; median $8.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ABOS
- Consensus EPS estimate-$0.3787 next reporting period, as of 2026-10-05
- Estimate change, 30 days$0.00 from -$0.3787, on 2026-09-04, 31-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is a clinical-stage entity with no approved products and a history of losses, which may require significant additional capital to reach commercialization.","Clinical trials for Alzheimer's disease are inherently high-risk, and the company's lead candidate or EBD program may fail to demonstrate the necessary efficacy or safety profile in late-stage trials.","The company's reliance on third-party collaborators for proprietary technology and delivery mechanisms introduces integration and operational risks."]
What changed in the latest 10-Q
AI-assisted comparison of ABOS's 10-Q filed 2026-08-12 against the prior one filed 2026-05-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-12) adds: 'Following this robust preclinical data from both in vitro and in vivo studies, in June 2026 we announced the nomination of two EBD development candidates, ACU301 and ACU401.'
- Newer filing (2026-08-12) adds: 'This stems from our July 2025 entry into a collaboration, option and license agreement with JCR Pharmaceuticals Co. Ltd., or JCR' (a reference to the timing of the July 2025 agreement).
- Newer filing (2026-08-12) adds: 'during the year ended December 31, 2025, we made an upfront license payment to JCR and, in June 2026, we exercised our exclusive option to develop two EBD development candidates, which required an option exercise payment of $9.25 million that was paid to JCR in July 2026.'
- Removed:
- Older filing (2026-05-12) contains 'if we exercise our exclusive option to develop up to two development candidates, JCR will be eligible for an option exercise payment of $9.25 million. We currently anticipate that we will exercise our option to license two compounds developed as part of our collaboration with JCR during the second quarter of 2026.' This text is removed in the newer filing.
- Reworded:
- Older filing (2026-05-12): 'Based on this data, an investigational new drug, or IND, application is targeted for mid-2027.' Newer filing (2026-08-12): 'Based on these developments, an investigational new drug, or IND, application for the lead candidate is targeted for mid-2027.'
- Older filing (2026-05-12): 'a blood-brain barrier-penetrating, Aß oligomer-targeted Enhanced Brain Delivery (EBD ™ ) therapy'. Newer filing (2026-08-12): 'a blood-brain barrier-penetrating, Aβ oligomer-targeted Enhanced Brain Delivery ™ (EBD ™ ) therapy'.
- Older filing (2026-05-12): 'In July 2025, we entered into a collaboration, option and license agreement with JCR... to develop an Aß oligomer-targeted EBD therapy'. Newer filing (2026-08-12): 'This stems from our July 2025 entry into a collaboration, option and license agreement with JCR... to develop an Aβ oligomer-targeted EBD therapy'.
- Older filing (2026-05-12): 'Under the terms of the agreement, in addition to an upfront license payment that we paid to JCR... JCR will be eligible for an option exercise payment of $9.25 million.' Newer filing (2026-08-12): 'Under the terms of the agreement, during the year ended December 31, 2025, we made an upfront license payment to JCR and, in June 2026, we exercised our exclusive option to develop two EBD development candidates, which required an option exercise payment of $9.25 million that was paid to JCR in July 2026.'
- Newer filing (2026-08-12) reformats 'Enhanced Brain Delivery ™ (EBD ™ )' with the trademark symbol placement changed compared to the older filing's 'Enhanced Brain Delivery (EBD ™ )'.
- Notes:
- The text of both filings ends mid-sentence in the source extract, so only the provided portions were compared.
Risk Factors
- Added:
- Newer filing (2026-08-12) adds risk factor disclosure stating the company anticipates it will no longer qualify as an 'emerging growth company' as of December 31, 2026, but will remain a 'smaller reporting company.'
- Newer filing (2026-08-12) adds risk factor disclosure describing the loss of emerging growth company exemptions, including the auditor attestation requirements of Section 404 and reduced executive compensation disclosure obligations.
- Newer filing (2026-08-12) adds risk factor disclosure about the company having elected to delay adopting new or revised accounting standards and that its financial statements may not be comparable to companies that complied with accounting pronouncements as of public company effective dates.
- Newer filing (2026-08-12) adds risk factor disclosure about continuing to qualify as a smaller reporting company and the scaled disclosure accommodations available.
- Newer filing (2026-08-12) adds disclosure that Daniel O'Connell entered into a Rule 10b5-1 trading plan on June 29, 2026 and a separate Rule 10b5-1 trading plan on June 30, 2026.
- Newer filing (2026-08-12) adds disclosure that Matthew Zuga entered into a Rule 10b5-1 trading plan on June 29, 2026 and a separate Rule 10b5-1 plan on June 29, 2026.
- Newer filing (2026-08-12) adds disclosure that Amy Schacterle entered into a Rule 10b5-1 trading plan on June 30, 2026 and a separate Rule 10b5-1 plan on June 30, 2026.
- Newer filing (2026-08-12) adds heading 'Officer and Director Trading Arrangements' under Item 5.
- Newer filing (2026-08-12) adds a section under Item 5 titled 'Approval of Amended and Restated 2021 Plan' disclosing stockholder approval on June 3, 2026 of the Company's Amended and Restated 2021 Equity Incentive Plan to increase shares by 10,000,000.
- Removed:
- Older filing (2026-05-12) disclosed that Matthew Zuga terminated a Rule 10b5-1 trading plan adopted December 31, 2025; this disclosure is absent in the newer filing.
- Older filing (2026-05-12) disclosed that Jeffery Ives entered into a Rule 10b5-1 trading plan on March 31, 2026; this disclosure is absent in the newer filing.
- Older filing (2026-05-12) disclosed that Derek Meisner entered into Rule 10b5-1 trading plans on March 31, 2026; this disclosure is absent in the newer filing.
- Reworded:
- Newer filing (2026-08-12) changes the introductory sentence in Item 1A from 'There have been no material changes to the risk factors as described in our Annual Report' to add 'except as follows:' followed by the new risk factor discussion.
- Newer filing (2026-08-12) changes the time period in Item 5 from 'During the three months ended March 31, 2026' to 'During the three months ended June 30, 2026'.
- Notes:
- The newer filing text appears truncated mid-sentence in the 'Approval of Amended and Restated 2021 Plan' section; the excerpt ends with 'remove the automatic' followed by 'evergreen' shar'.
- Item 6 Exhibits and Signatures sections appear in the older filing excerpt but are not present in the newer filing excerpt, which instead shows a truncated Item 5 section; the comparison is limited to the provided excerpts.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-040 buys · 4 sells ($89512) — 2 selling insiders
Most recent open-market transaction: 2026-06-17. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ABOS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ABOS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,875,296
- Reported value $10,347,042
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ABOS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ABOS had 2,804,144 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ABOS had 3.88% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.16 days to cover at the same settlement.
- Reported short interest (shares) 2,804,144
- Short interest (% of shares outstanding) 3.88%
- Prior settlement (shares) 3,163,185
- Reported change -11.35%
- Days to cover (reported) 8.16
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Biogen (BIIB)
- Eli Lilly (LLY)
- Roche (RHHBY)
- Eisai (ESALY)
- Prothena (PRTA)
- Anavex Life Sciences (AVXL)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ABOS vs…
ACUMEN PHARMACEUTICALS INC is found in…
Frequently asked questions
What does ACUMEN PHARMACEUTICALS INC (ABOS) do?
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for Alzheimer’s disease. Its lead candidate, sabirnetug (ACU193), is an IgG2 monoclonal antibody designed to selectively target toxic soluble amyloid-beta oligomers (AβOs). The company is also developing an Enhanced Brain Delivery (EBD) program that utilizes blood-brain barrier-penetrating technology to create next-generation, subcutaneous-administered antibody treatments.
What sector is ACUMEN PHARMACEUTICALS INC (ABOS) in?
ACUMEN PHARMACEUTICALS INC (ABOS) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are ACUMEN PHARMACEUTICALS INC's (ABOS) competitors?
Notable peers of ACUMEN PHARMACEUTICALS INC (ABOS) include Biogen, Eli Lilly, Roche, Eisai and Prothena. This peer set is informational only — not financial advice.
Is ACUMEN PHARMACEUTICALS INC (ABOS) overbought or oversold right now?
ACUMEN PHARMACEUTICALS INC (ABOS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ABOS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.